Guardant Health reported a 44% year-over-year rise in Q2 revenue, driven by oncology testing growth and expanding coverage for its Shield blood screening assay. The company also pointed to the June FDA approval of Guardant360 Liquid CDx as a companion diagnostic for Boehringer Ingelheim’s Hernexeos in HER2-mutant advanced non-small cell lung cancer.